Soumi Chakraborty

Ms. Soumi Chakraborty

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
GRGourav Rakshit
Gourav Rakshit
SCSoumi Chakraborty
Soumi Chakraborty
Sanjib BhaktaSanjib Bhakta
Sanjib Bhakta
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash
Pyrazoline scaffolds have attracted significant interest in medicinal chemistry due to their broad spectrum of pharmacological activities. Pyrazole-based drugs are either already approved or are currently undergoing clinical trials across a range of therapeutic areas. Pyrazolines (Δ2-pyrazolines or 2-pyrazoline or 4,5-dihydropyrazoles) evolved as cyclic analogues of thioacetazone and were explored for enhanced antitubercular activity over the past five decades. The scope of this review focused on how extensively the chemical space around pyrazolines has been explored in relation to their antitubercular activity, rather than presenting a general structure–activity relationship (SAR) account. In this exercise, we covered key molecular modifications, including rationale substitutions and conjugations, aimed at enhancing the potency in general. Additionally, information pertaining to in vitro/in silico target interaction and ADMET studies are also covered. A dedicated section is included to showcase target-oriented strategies (InhA, cytochrome P450 14α-sterol demethylase, and enzymes involved in the mycobactin biosynthesis pathway), recent patents, suggested schemes for reported pyrazolines, and an overview of research methodologies and evaluation models. We believe that this review will enable medicinal chemists to map unexplored chemical space in identifying critical research gaps. This is essential for the rational design and development of potent antitubercular agents against tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and other non-tubercular mycobacterial diseases (NTMD).

11 November 2025 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
SCSoumi Chakraborty
Soumi Chakraborty
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash
Tuberculosis (TB) remains a major global health concern, underscoring the urgent need for innovative therapeutic approaches. In this study, we aimed to identify potential inhibitors of phenyloxazoline synthase MbtB, an essential enzyme involved in the iron acquisition pathway of Mycobacterium tuberculosis and a promising target for drug development. To this end, a curated library of FDA-approved drugs from the ZINC database was systematically screened to uncover compounds with potential inhibitory activity against MbtB.Multiple conformations of the substrate’s transition state structure were utilized as query models. Conformational ensembles for both the query molecules and compounds within the FDA-approved drug library were generated using Balloon (v1.8.2). Virtual screening was then conducted using ShaEP (v1.4.0), which evaluates shape and electrostatic potential similarity, resulting in the identification of several promising candidate inhibitors.Molecular dynamics simulation was performed to understand molecular-level interaction between the top 5 hits and the target protein. Top hits will be procured, testing their anti-TB activity in ion-rich and ion-deprived media, as reported in earlier publications.